HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about FDA reforming clinical trials, a Pfizer setback, and much more news
Pfizer disclosed that its experimental lung cancer drug, sigvotatug vedotin, failed to show a statistically significant improvement over docetaxel in a clinical trial. The U.S. Food and Drug Administration announced a pilot program to accelerate early-stage clinical trials, aiming to reduce development timelines and counter Chinese dominance in the field.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
- STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
- STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- STAT+: Johnson & Johnson advances IBD therapy, despite trial miss